No Data
PTC Therapeutics Rallies 18% on EU Authorization Update for Translarna
Wells Fargo Starts Wave Life Sciences at Buy, Cites Valuation
WAVE Life Sciences Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on WAVE Life Sciences (NASDAQ:WVE) in the last three months.The table below summarizes their recent
WAVE Life Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 88.36% Wells Fargo → $11 Initiates Coverage On → Overweight 04/01/2024 191.1% Truist Securities
Express News | Wave Life Sciences Ltd : Wells Fargo Initiates With Overweight Rating; Price Target $11
Buy Rating on Wave Life Sciences: Promising Pipeline and Market Potential